NextBiomed nearing 80% enrollment in FDA Nexsphere-F trial
NextBiomedical said its FDA trial for Nexsphere-F is about 80% enrolled and progressing as planned, and it is seeking a strategic U.S. partner to support market entry.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.